{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"146.9","value":"5505"},{"groupId":"OG001","spread":"63.7","value":"8955"},{"groupId":"OG002","spread":"75.4","value":"12100"},{"groupId":"OG003","spread":"34.2","value":"2538"},{"groupId":"OG004","spread":"51.1","value":"8529"},{"groupId":"OG005","spread":"71.7","value":"2288"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63.5","value":"13080"},{"groupId":"OG001","spread":"124.0","value":"14130"},{"groupId":"OG002","spread":"24.0","value":"19140"},{"groupId":"OG003","spread":"22.3","value":"26360"},{"groupId":"OG004","spread":"92.6","value":"7468"},{"groupId":"OG005","spread":"71.0","value":"20640"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose level of 100 mg until MTD or MED achieved.","id":"OG000","title":"Phase 1: FT-2102 100 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG001","title":"Phase 1: FT-2102 150 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally QD in 28-day cycles at dose levels of 300 mg until MTD or MED achieved.","id":"OG002","title":"Phase 1: FT-2102 300 mg QD (Single Agent)"},{"description":"Participants with AML or MDS received single agent FT-2102 orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG003","title":"Phase 1: FT-2102 150 mg BID (Single Agent)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\\^2) orally QD in 28-day cycles at dose levels of 150 mg until MTD or MED achieved","id":"OG004","title":"Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy)"},{"description":"Participants with AML or MDS received combination therapy (FT-2102 + azacitidine 75 mg/m\\^2) orally BID in 28-day cycles at dose levels of 150 mg until MTD or MED achieved.","id":"OG005","title":"Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic (PK) analysis set included those participants for whom it was possible to calculate at least 1 primary PK parameter and who had no major protocol deviations thought to influence the absorption, distribution, metabolism, and excretion of the FT-2102. Here, number anaylzed (n) = participants with available data for specific timepoints.","reportingStatus":"POSTED","timeFrame":"Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)","title":"Phase 1: Area Under the Curve (AUClast) for FT-2102","type":"SECONDARY","unitOfMeasure":"Hour*nanograms per millilitre (h*ng/mL)"}